In 2027, Walmart is making more than 250 medications — including some GLP-1s, insulin and inhalers — available for employees at no cost. While GLP-1s have already been available to employees with Type 2 diabetes, the drugs will be accessible…
GLP-1s
Roughly 1.1 million Medicare beneficiaries have signed up to access discounted GLP-1s through CMS’ Bridge model, HHS Chief Counselor Chris Klomp said during an Oct. 7 Wall Street Journal event. The pilot launched July 1, rolling out to Medicare Part…
The FDA has received reports in recent months that two people died after taking illicit products claiming to be retatrutide, Eli Lilly’s experimental weight loss drug, according to FDA documents reviewed by CBS News in an Oct. 13 report. The…
Evidence is growing that GLP-1 receptor agonists, the drugs best known for treating diabetes and obesity, could also have a role in addiction care. A study published in March found that GLP-1 use was associated with 75% lower odds of…
The Trump administration is preparing a stopgap that would allow certain previously restricted peptides to be sold temporarily while federal health officials write new regulations, according to an Oct. 7 Washington Post report citing two people familiar with the matter.…
Advertisement
The World Health Organization has issued its first guidelines addressing obesity among children and adolescents, including recommendations on when medications and bariatric surgery should be considered. WHO does not recommend pharmacological treatment, bariatric surgery or weight-loss devices for children ages…
obesity, with a phase 2 trial finding that the amylin analogue petrelintide reduced body weight by up to 10.7% through week 42, according to a study published Sept. 29 in The Lancet Diabetes & Endocrinology. Here are five things to…
Medicare uptake, off-label prescribing and new safety questions are shaping the GLP-1 landscape. Here are five GLP-1 updates to know.
People taking GLP-1s are more than four times as likely to report nail detachment as similar patients with obesity or type 2 diabetes who don’t take the drugs, according to research presented Oct. 1 at the European Academy of Dermatology…
Patients receiving injectable GLP-1 therapy through NYU Langone Health Specialty Pharmacy had a 3.9% first-year discontinuation rate, according to research shared Sept. 25 in The American Journal of Managed Care. Here are four things to know: